Cailin Conner

DocwireNews

Stem cell gene therapy showed significant potential as a curative approach for the hereditary blood disorder sickle cell disease (SCD), according to a recent clinical trial published in the <a href="https://www.nejm.org/doi/10.1056/NEJMoa2215643" target="_blank" rel="noopener">New England Journal of Medicine</a>.According to the study, elevated levels of fetal hemoglobin in red blood cells can mitigate the complications of SCD. Fetal hemoglobin, unlike its adult counterpart, does not polymerize and cause red blood cells to deform under hypoxic conditions.&ldquo;OTQ923, a clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-edited CD34+ hematopoietic stem- and progenitor-cell (HSPC) product, has a targeted disruption of the HBG1&nbsp;and&nbsp;HBG2&nbsp;(&gamma;-globin) gene promoters that increases fetal hemoglobin expression in red-cell progeny,&rdquo; investigators wrote.The study employed a tiling CRISPR-Cas9 screen to target the HBG1 and HBG2 gene promoters in CD34+ HSPC product. Using this process, which involved 72 guide RNAs, they aimed to increase the expression of fetal hemoglobin-immunostaining erythroblasts (F cells) in&nbsp;erythroid-differentiated progeny. The guide RNA, gRNA-68, demonstrated the highest efficacy in elevating fetal hemoglobin levels and was chosen for further clinical development.In preclinical tests, CRISPR-Cas9-edited CD34+ HSPC product, sourced from healthy donors and individuals with SCD, &ldquo;sustained on-target editing with no off-target mutations and produced high levels of fetal hemoglobin after in vitro differentiation or xenotransplantation into immunodeficient mice.&rdquo;During the study, 3 patients who underwent myeloablative conditioning received autologous OTQ923, with a subsequent follow-up lasting 6 to 18 months. The results showed successful engraftment and consistent induction of fetal hemoglobin, constituting 19.0% to 26.8% of total hemoglobin, with fetal hemoglobin evenly distributed within red blood cells (F cells making up 69.7% to 87.8% of red cells). Importantly, the manifestations of SCD decreased over the follow-up period.&ldquo;CRISPR-Cas9 disruption of the&nbsp;HBG1&nbsp;and&nbsp;HBG2&nbsp;gene promoters was an effective strategy for induction of fetal hemoglobin,&rdquo; investigators wrote. &ldquo;Infusion of autologous OTQ923 into 3 participants with severe sickle cell disease resulted in sustained induction of red-cell fetal hemoglobin and clinical improvement in disease severity.&rdquo;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Stem Cell Gene Therapy Shows Promise as Treatment for Sickle Cell Disease

Sickle Cell Disease

Stem cell gene therapy showed potential as a curative approach for the hereditary blood disorder sickle cell disease.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe